Salud financiera de hoja de balance de Veracyte

Salud financiera controles de criterios 6/6

Veracyte tiene unos fondos propios totales de $1.1B y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $1.1B y $70.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$216.45m
Patrimonio	US$1.04b
Total pasivo	US$70.80m
Activos totales	US$1.11b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Valuing Veracyte Stock

Oct 03

Análisis de la situación financiera

Pasivos a corto plazo: VCYTLos activos a corto plazo ($271.2M) de la empresa superan a sus pasivos a corto plazo ($57.3M).

Pasivo a largo plazo: VCYTLos activos a corto plazo ($271.2M) superan a sus pasivos a largo plazo ($13.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: VCYT está libre de deudas.

Reducción de la deuda: VCYT no tiene deuda en comparación con hace 5 años, cuando su ratio deuda/fondos propios era de 31.7%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable VCYT tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de free cash flow.

Pronóstico de cash runway: VCYT no es rentable pero tiene suficiente liquidez para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 24% al año.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Veracyte

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Co-Founder & Executive Chairwoman exercised options to buy US$188k worth of stock.

Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access

Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-National, Randomized Stampede Platform Protocol

Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for Car T-Cell Therapy in Patients with Large B-Cell Lymphoma

Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors

Co-Founder & Executive Chairwoman recently sold US$3.4m worth of stock

Consensus estimates of losses per share improve by 10%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Revises Revenue Guidance for the Year 2022

Consensus forecasts updated

Veracyte, Inc. Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

Veracyte, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Veracyte, Inc. Announces New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

CEO & Director recently bought US$980k worth of stock

Veracyte, Inc. Announces the Publication of Data Reinforcing the Clinical Utility of the Decipher Prostate Genomic Classifier

Veracyte, Inc. Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

Veracyte, Inc. Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

Veracyte, Inc. Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

Veracyte: Not A Healthy Diagnosis

Consensus estimates of losses per share improve by 18%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2022

Veracyte, Inc. to Report Q1, 2022 Results on May 03, 2022

Insider notifies of intention to sell stock